SEC Tracker
Get the app

BeyondSpring BYSI

BeyondSpring FY 2024: net loss $11.1M

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers BeyondSpring reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$11.1MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Cash and cash equivalents$2.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  3. Cash from operations−$16.4MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when BeyondSpring files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025
  2. Seres Therapeutics MCRB public float $72M, Jun 30, 2025
  3. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  4. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  5. Volitionrx VNRX public float $73M, Jun 30, 2025